A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride (Ra-223) in HER2- hormone receptor+ breast cancer patients with bone metastases.

A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy (HT) ± radium-223 dichloride (Ra-223) in HER2- hormone receptor+ breast cancer patients (pts) with bone metastases (mets).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps1104 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS1104-TPS1104

Author(s):

Robert E. Coleman ◽

Liping Huang ◽

Oana Petrenciuc ◽

Paola Zaccarini

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Cancer Patients ◽

Hormone Receptor ◽

Controlled Trial ◽

Phase 2 ◽

Breast Cancer Patients ◽

Double Blind ◽

Double Blind Placebo ◽

Radium 223

Abstract OT1-04-05: A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative, hormone receptor–positive breast cancer and bone metastases

10.1158/1538-7445.sabcs16-ot1-04-05 ◽

2017 ◽

Author(s):

HS Rugo ◽

KC Drumea ◽

M Campone ◽

A Barnadas ◽

O Petrenciuc ◽

...

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Hormone Receptor ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Radium 223 ◽

Abstract OT1-04-04: A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride in HER2-negative, hormone receptor–positive breast cancer patients with bone metastases

10.1158/1538-7445.sabcs16-ot1-04-04 ◽

2017 ◽

Author(s):

RE Coleman ◽

G Fried ◽

O Petrenciuc ◽

A Sawhney ◽

R Li ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Controlled Trial ◽

Phase 2 ◽

Breast Cancer Patients ◽

Double Blind ◽

Double Blind Placebo ◽

Radium 223 ◽

A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive breast cancer and bone metastases.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps621 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS621-TPS621 ◽

Cited By ~ 1

Author(s):

Hope S. Rugo ◽

Rui Li ◽

Oana Petrenciuc ◽

Amily Zhang ◽

Robert E. Coleman

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Hormone Receptor ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Radium 223 ◽

A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive breast cancer and bone metastases

Annals of Oncology ◽

10.1093/annonc/mdw365.89 ◽

2016 ◽

Vol 27 ◽

pp. vi97 ◽

Cited By ~ 1

Author(s):

H. Rugo ◽

O. Petrenciuc ◽

A. Zhang ◽

R. Li ◽

R.E. Coleman

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Hormone Receptor ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Radium 223 ◽

Abstract OT2-01-05: A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy ± radium-223 dichloride in human epidermal growth factor receptor 2–negative, hormone receptor–positive breast cancer patients with bone metastases

10.1158/1538-7445.sabcs15-ot2-01-05 ◽

2016 ◽

Author(s):

RE Coleman ◽

L Huang ◽

O Petrenciuc ◽

P Zaccarini ◽

HS Rugo

Keyword(s):

Controlled Trial ◽

Growth Factor Receptor ◽

Phase 2 ◽

Breast Cancer Patients ◽

Double Blind ◽

Double Blind Placebo ◽

Radium 223 ◽

Epidermal Growth ◽

Abstract PD08-04: Management of Hot Flashes in Breast Cancer Patients with Venlafaxine and Clonidine: A Double-Blind Placebo-Controlled Trial

10.1158/0008-5472.sabcs10-pd08-04 ◽

2010 ◽

Author(s):

AH Boekhout ◽

A Vincent ◽

J Bosch ◽

S Adriaansz ◽

J Foekema ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Controlled Trial ◽

Hot Flashes ◽

Breast Cancer Patients ◽

Double Blind ◽

Double Blind Placebo

Abstract OT2-01-11: A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in human epidermal growth factor receptor 2–negative, hormone receptor–positive breast cancer patients with bone metastases

10.1158/1538-7445.sabcs15-ot2-01-11 ◽

2016 ◽

Author(s):

HS Rugo ◽

L Huang ◽

O Petrenciuc ◽

P Zaccarini ◽

RE Coleman

Keyword(s):

Controlled Trial ◽

Growth Factor Receptor ◽

Phase 2 ◽

Breast Cancer Patients ◽

Double Blind ◽

Double Blind Placebo ◽

Radium 223 ◽

Epidermal Growth ◽

CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial

Trials ◽

10.1186/s13063-019-3643-6 ◽

2020 ◽

Vol 21 (1) ◽

Author(s):

Rob Coleman ◽

Janet Brown ◽

Emma Rathbone ◽

Louise Flanagan ◽

Amber Reid ◽

...

Keyword(s):

Breast Cancer ◽

Randomised Controlled Trial ◽

Bone Metastases ◽

Cancer Patients ◽

Study Protocol ◽

Controlled Trial ◽

Breast Cancer Patients ◽

Phase Ib ◽

Radium 223 ◽

Randomised Controlled

Clinical impact of melatonin on breast cancer patients undergoing chemotherapy; effects on cognition, sleep and depressive symptoms: A randomized, double-blind, placebo-controlled trial

PLoS ONE ◽

10.1371/journal.pone.0231379 ◽

2020 ◽

Vol 15 (4) ◽

pp. e0231379 ◽

Cited By ~ 1

Author(s):

Ana Claudia Souza Palmer ◽

Maxciel Zortea ◽

Andressa Souza ◽

Vinicius Santos ◽

Jorge Villanova Biazús ◽

...

Keyword(s):

Breast Cancer ◽

Depressive Symptoms ◽

Cancer Patients ◽

Controlled Trial ◽

Clinical Impact ◽

Breast Cancer Patients ◽

Double Blind ◽

Double Blind Placebo